Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

Biomarkers in Diabetic Retinopathy Treated With Faricimab vs Biosimilar Ranibizumab — Stella

Home/Diabetic Retinopathy (DR)/Biomarkers in Diabetic Retinopathy Treated With Faricimab vs Biosimilar Ranibizumab

View on ClinicalTrials.gov

Recruiting

Back to Diabetic Retinopathy (DR) trials

Biomarkers in Diabetic Retinopathy Treated With Faricimab vs Biosimilar Ranibizumab

Not a traditional drug trial — this study doesn't follow the standard phase structure.

Trial locations(1 site)

Croatia

University Hospital Osijek, Osijek

Key details

Sponsor

Osijek University Hospital

Enrollment target

~100 participants

Started

March 2026

Primary completion

June 2027

Age range

18 Years and older

Last updated April 2026

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.